Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Beigene Ltd Ads (BGNE)

Beigene Ltd Ads (BGNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

NVS : 96.68 (-0.01%)
BMY : 66.26 (-0.72%)
AMGN : 251.74 (+1.40%)
BGNE : 364.03 (+2.06%)
China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its anti-PD-1 antibody...

BGNE : 364.03 (+2.06%)
Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene

Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.

JNJ : 162.99 (+0.13%)
NVS : 96.68 (-0.01%)
ABBV : 112.82 (+0.57%)
BGNE : 364.03 (+2.06%)
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

--BeiGene to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales

NVS : 96.68 (-0.01%)
BGNE : 364.03 (+2.06%)
Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand's Next-Generation, Multi-Functional mRNA Technology

Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer and other diseases, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they...

BGNE : 364.03 (+2.06%)
BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate...

JPM : 136.25 (-1.30%)
BGNE : 364.03 (+2.06%)
BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)

--XGEVA(R) (denosumab) from BeiGene's strategic collaboration with Amgen is included in one approved indication

BGNE : 364.03 (+2.06%)
COVID-19 Vaccines are Being Distributed, is Pfizer Stock Still a Buy?

Pfizer (PFE) has emerged as one of the winners in the race for an effective COVID-19 vaccine. It was the first company to receive commercial authorization from multiple regulatory bodies in the U.S. and...

PFE : 36.59 (-0.38%)
JNJ : 162.99 (+0.13%)
TEVA : 12.32 (-1.83%)
BGNE : 364.03 (+2.06%)
BeiGene Announces the Approval in China of BLINCYTO(R) (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical...

AMGN : 251.74 (+1.40%)
BGNE : 364.03 (+2.06%)
BeiGene Presents Clinical Data on BRUKINSA(R) (Zanubrutinib) in B-Cell Malignancies and Waldenstrom's Macroglobulinemia at the 62nd ASH Annual Meeting

--Zanubrutinib demonstrated deep and durable responses in relapsed/refractory Waldenstrom's Macroglobulinemia patients in a pivotal Phase 2 trial in China; data submitted for regulatory approval in China...

BGNE : 364.03 (+2.06%)
BeiGene Announces Data on BRUKINSA(R) (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting

--Zanubrutinib demonstrated an overall response rate of nearly 95 percent and a sustained progression-free survival in treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma patients...

BGNE : 364.03 (+2.06%)
BeiGene Announces Pricing of Public Offering by Selling Shareholders

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the pricing of an underwritten...

BGNE : 364.03 (+2.06%)
BeiGene Launches Proposed Public Offering by Selling Shareholders

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the commencement of an underwritten...

BGNE : 364.03 (+2.06%)
BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate...

BGNE : 364.03 (+2.06%)
BeiGene Announces the Approval of XGEVA(R) (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical...

AMGN : 251.74 (+1.40%)
BGNE : 364.03 (+2.06%)
BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the RATIONALE 303 trial...

BGNE : 364.03 (+2.06%)
BeiGene Reports Third Quarter 2020 Financial Results

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights,...

BGNE : 364.03 (+2.06%)
BeiGene Announces Data on BRUKINSA(R) (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its BTK...

BGNE : 364.03 (+2.06%)
BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage...

BGNE : 364.03 (+2.06%)
All You Need to Know About BeiGene, Ltd. (BGNE) Rating Upgrade to Buy

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BGNE : 364.03 (+2.06%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar